

Program Agenda:

"Precision & Innovative Medicine and Health Technology Assessment"

Monday, June 28, 2021

Free Virtual seminar

15:00 – 17:30 CET


Precision & innovative medicine aims to tailor disease prevention, diagnosis and treatment to the individual patient, based on their individual features.

Health Technology Assessment (HTA) is an instrumental part of the process in obtaining reimbursement and market access for pharmaceuticals and medical products in countries around the world.

The Basel Biometric Society (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a scientific meeting on these relevant topics with experts from industry, academia and European regulatory/HTA bodies

Final Agenda

15:00-15:05	Welcome and Introduction – Fred Sorenson , Xcenda, Switzerland
15:05-15:20	"The UK's Innovative Licensing and Access Pathway (ILAP) for medicines – A joint MHRA, NICE & SMC initiative" Dan O'Connor , MHRA, UK
15:20-15:35	"IMPACT HTA - Recommendations for Developing Rare Disease Treatments" Karen Facey , University of Edinburgh, UK
15:35-15:50	"Adjusting Global Survival to Make Results More Relevant and Generalizable to Local Markets" Paul Cislo, Jinma Ren and Joseph C. Cappelleri , Pfizer, USA
15:50-16:05	"Net benefit and correlation between benefit and harms" Marc Buyse , IDDI and University of Hasselt, Belgium
16:05-16:15	Panel discussion with questions for all previous speakers
16:15-16:20	5-minute break
16:20-16:35	"Closing the efficacy to effectiveness gap: Generalizing from RCTs to real world populations" Mark Belger and Marie-Ange Paget , Eli Lilly UK & France
16:35-16:50	"Assessments and reimbursement of gene expression signature tests in Europe" Kirsten Herrmann , Exact Sciences, Germany
16:50-17:05	"Bridging the gap between Regulatory & HTA approval for Precision Medicine therapies: a case study from the Netherlands" Janneke Boersma , Roche, Netherlands
17:05-17:20	"Acceptance and Uptake of Cell and Gene Therapies: Lessons Learned and Future Focus" Tay Salimullah , Novartis Gene Therapies, Switzerland & USA
17:20-17:30	Panel discussion with questions for all previous speakers since the break
17:30	End of the meeting



Venue

Virtual seminar

Registration

Interested persons can still register by clicking on the following link:

[Precision Medicine and Health Technology Assessment \(HTA\) \(google.com\)](#)

Please add this meeting in your own calendar

Questions about the presentations can be asked in a chat during the presentations.

For information regarding registration and/or the scientific content including questions in advance for the speakers, please feel free to contact any one of the webinar organizers:

Pierre Verweij, Idorsia (BBS & EFSPI)
Pierre.Verweij@idorsia.com

Egbert Biesheuvel, Danone (EFSPI)
Egbert.Biesheuvel@danone.com

Fred Sorenson, Xcenda (BBS)
Fred.Sorenson@xcenda.com